Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Testing a New Treatment for Crohn’s Disease
Clinical Breakthroughs

Testing a New Treatment for Crohn’s Disease

By Anna WilliamsJan 6, 2017
Share
Facebook Twitter Email
Stephen-Hanauer-2014
Stephen Hanauer, MD, the Clifford Joseph Barborka Professor of Medicine in the Division of Gastroenterology and Hepatology, is a member of the steering committee for trials of ustekinumab in inflammatory bowel disease.

Patients with moderate to severe Crohn’s disease showed significant improvement on a drug called ustekinumab, according to the results of phase III clinical trials published in the New England Journal of Medicine.

The study was co-authored by Stephen Hanauer, MD, the Clifford Joseph Barborka Professor of Medicine in the Division of Gastroenterology and Hepatology.

Crohn’s disease is an inflammatory condition of the gastrointestinal tract, characterized by severe abdominal pain, diarrhea and weight loss. Current therapies, such as immunosuppressants, can help control symptoms of the disease, but they have limited efficacy and can carry an increased risk of infection.

Ustekinumab — a drug already used in the treatment of psoriasis and psoriatic arthritis — is a monoclonal antibody that blocks interleukin-12 and interleukin-23, proteins which are known to play a role in the inflammatory response.

In the study, investigators tested the drug in two trials of more than 1,300 patients with untreated Crohn’s. Participants were randomly assigned to receive one of two different doses of ustekinumab or a placebo over the course of eight weeks. Those who showed a clinical response to the drug were also then enrolled in a 44-week maintenance trial.

In all instances, ustekinumab was found to be significantly better than the placebo in inducing a clinical response, as well as maintaining remission. Further, rates of adverse side effects were similar in both the ustekinumab and placebo groups.

“The inflammatory bowel disease (IBD) program within the Digestive Health Center is actively engaged in clinical trials involving new therapies for Crohn’s disease and ulcerative colitis, with over a dozen protocols testing different mechanisms of action in a broad range of IBD patients,” Hanauer said.

Ustekinumab was approved by the FDA for moderately to severely active Crohn’s disease in September. The study was funded by Janssen Research and Development, which manufactures the drug. Hanauer is a paid consultant for Janssen.

Patient Care Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.